SCHEMBL1847756

SCHEMBL1847756

FCCNCc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.73
KMT2A Q03164 1/20 0.73
TDP1 Q9NUW8 1/20 0.73
MAOA P21397 1/20 0.64
CHRM2 P08172 1/20 0.61
GAA P10253 1/20 0.61
MAPT P10636 1/20 0.61
SIGMAR1 Q99720 3/20 0.57
DRD4 P21917 1/20 0.53
MPO P05164 2/20 0.50
DPP7 Q9UHL4 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
ADH1B P00325 1/20 0.46
ADH1C P00326 1/20 0.46
ADH1A P07327 1/20 0.46
ADH7 P40394 1/20 0.46
IDO1 P14902 2/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9865615 0.86 MAOA (0.72) MEN1KMT2ATDP1MAOACHRM2
SCHEMBL5764 0.85 MEN1 (1.00) MEN1KMT2ATDP1MAOACHRM2
SCHEMBL8498461 0.82 LTA4H (0.67) MEN1KMT2ATDP1MAOADRD4
Water SCHEMBL4230715 0.82 MEN1 (0.94) MEN1KMT2ATDP1MAOACHRM2
SCHEMBL4922899 0.82 MEN1 (0.94) MEN1KMT2ATDP1MAOACHRM2
Ammonia Solution, Strong SCHEMBL6678345 0.82 MEN1 (0.94) MEN1KMT2ATDP1MAOACHRM2
SCHEMBL5040570 0.82 MEN1 (0.94) MEN1KMT2ATDP1MAOACHRM2
Hydrochloric Acid SCHEMBL5845845 0.82 MEN1 (0.94) MEN1KMT2ATDP1MAOACHRM2
SCHEMBL4913828 0.82 MEN1 (0.94) MEN1KMT2ATDP1MAOACHRM2
Hydrochloric Acid SCHEMBL11324591 0.82 MEN1 (0.94) MEN1KMT2ATDP1MAOACHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025107026-A1 TSPO LIGANDS THE UNIVERSITY OF SYDNEY (AU) 2025-05-30 WO disclosed
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-02-02 US disclosed
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-02-02 US disclosed
EP-3515912-B1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NAT RECH SCIENT (FR) 2020-10-14 EP disclosed
EP-3515912-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES Centre National De La Recherche Scientifique (FR) 2019-07-31 EP disclosed
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-07-11 US disclosed
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-07-11 US disclosed
WO-2018055316-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-29 WO disclosed
US-9840731-B2 Preservation of biological materials in non-aqueous fluid media GENTEGRA, LLC (US) 2017-12-12 US disclosed
US-20150267245-A1 PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA GENTEGRA, LLC (US) 2015-09-24 US disclosed
US-20120283448-A1 METHOD FOR PRODUCING 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND PRODUCTION INTERMEDIATE THEREOF KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2011-08-04 US disclosed
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2011-08-04 US disclosed
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2011-08-04 US disclosed
EP-2323974-A1 METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO Ube Industries, Ltd. (JP) 2011-05-25 EP disclosed
EP-2243769-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE FLUOROAMINE Central Glass Company, Limited (JP) 2010-10-27 EP disclosed
US-20100152463-A1 Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2010-06-17 US disclosed
US-20100152463-A1 Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2010-06-17 US disclosed
WO-2010022001-A1 METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO IM&T RESEARCH, INC. (US) 2010-02-25 WO disclosed
US-20080274046-A1 Radiolabelling UNIVERSITY OF MANCHESTER, THE (GB) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152463-A1 Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto PFAS, AGPS, FDPS MEN1 2099/4885KMT2A 3317/4885TDP1 940/4885
US-20120283448-A1 METHOD FOR PRODUCING 3,4-DISUBSTITUTED PYRROLIDINE DERIVATIVE AND PRODUCTION INTERMEDIATE THEREOF CYP4F3, PFAS, CYP4F2 MEN1 2811/4885KMT2A 4467/4885TDP1 2427/4885
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto PFAS, AGPS, FDPS MEN1 1047/4885KMT2A 3884/4885TDP1 1032/4885
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases PSEN2, CLN6, MAPT MEN1 672/4885KMT2A 4069/4885TDP1 1006/4885
US-20080274046-A1 Radiolabelling MCHR1, CHRM1, MCHR2 MEN1 4/4885KMT2A 1360/4885TDP1 2136/4885
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES PSEN2, SNCA, MAPT MEN1 927/4885KMT2A 4162/4885TDP1 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.